



PRESS RELEASE

## **Collectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019**

**June 26, 2019 – New York** – Collectis S.A. held its Combined Shareholders Meeting (Euronext Growth: ALCLS; Nasdaq: CLLS) on June 25, 2019 at its head office in Paris.

At the meeting, during which more than 68% of voting rights were exercised, Resolutions 1 through 18, 23 and 24 were adopted. Resolutions 19 through 22 and Resolution 25 were rejected. The detailed results of the vote and the resolutions are available on the company's website [www.collectis.com/en/investors/general-meetings/](http://www.collectis.com/en/investors/general-meetings/).

### **About Collectis**

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 19 years of expertise in gene editing – built on its flagship TALEN<sup>®</sup> technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: [www.collectis.com](http://www.collectis.com)

Talking about gene editing? We do it. TALEN<sup>®</sup> is a registered trademark owned by Collectis.

**For further information, please contact:**

### **Media contacts:**

Jennifer Moore, VP of Communications, 917-580-1088, [media@collectis.com](mailto:media@collectis.com)  
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, [ckasunich@kcsa.com](mailto:ckasunich@kcsa.com)

### **IR contact:**

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, [simon.harnest@collectis.com](mailto:simon.harnest@collectis.com)

###